Feature | November 01, 2013

Clinical Trial Finds CoreValve Reduces Rate of Death, Stroke in Patients With Aortic Stenosis

Results of the CoreValve Extreme Risk trial presented at TCT 2013

heart valve repair hybrid or cath lab structural heart tct medtronic corevalve

November 1, 2013 — In a clinical trial, the Medtronic Corevalve self-expanding transcatheter aortic valve met the key performance objective of reducing death and stroke in patients with severe aortic stenosis at “extreme risk” for surgery. Results of the CoreValve Extreme Risk trial were presented at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013) in San Francisco.
 
The CoreValve Extreme Risk trial was a prospective, multicenter, controlled, non-randomized, single-arm investigation evaluating the safety and efficacy of the transfemorally implanted CoreValve self-expanding transcatheter heart valve. The trial was conducted in 487 patients with symptomatic, severe aortic stenosis. 
 
All patients were deemed to be at extreme risk for surgical aortic valve replacement, and were thus treated with the Corevalve device. The primary endpoint was a composite of all-cause mortality or major stroke rate at 12 months; the Kaplan-Meier determined event rate was compared with a pre-specified objective performance goal (OPG). 
 
Of the 487 patients enrolled in the study, 471 had an attempted implantation and were designated as the primary "as treated" analysis population. Patients were elderly (83.1 years), and were severely symptomatic (NYHA class III or IV, 91.9 percent). The Society for Thoracic Surgery predicted risk of mortality was 10.3 percent ± 5.6 percent and was > 15 percent in 17.6 percent of patients. 
 
At 12 months, the composite rate of death or major stroke was 25.5 percent, significantly below the 95 percent confidence interval of the performance goal, which was set at 43 percent. While moderate paravalvular leak was observed in 11 percent of patients at one month, 80 percent of patients with moderate paravalvular (PV) leak at one month who survived to one year experienced a reduction in PV leak over time.
 
“The CoreValve Extreme Risk study achieved its primary endpoint of a reduction in all cause mortality or major stroke at one year compared to a rigorously defined OPG,” said Jeffrey Popma, M.D., lead investigator, director, Interventional Cardiology, Beth Israel Deaconess Medical Center.
 
Medtronic has three FDA IDE trials evaluating the Corevalve for high-risk and extreme-risk surgical patients and in patients at intermediate risk for open-heart aortic valve replacement (SURTAVI Trial).
 
For more information: www.crf.org, www.medtronic.com

Related Content

Feature | Heart Valve Technology

July 8, 2021 – Xeltis announced it started the first pivotal trial for a synthetic polymer restorative pulmonary valve ...

Home July 08, 2021
Home
News | Heart Valve Technology

June 2, 2021 – LivaNova announced June 1 it successfully completed the initial closing of the divestiture of its heart ...

Home June 02, 2021
Home
News | Heart Valve Technology

May 4, 2021 – A new study, presented at the 2021 American Association for Thoracic Surgery (AATS) 101st annual meeting ...

Home May 04, 2021
Home
News | Heart Valve Technology

March 18, 2020 — A groundbreaking new study led by University of Minnesota Twin Cities researchers from both the College ...

Home March 18, 2021
Home
News | Heart Valve Technology

February 4, 2021 — Transcatheter aortic valve replacement (TAVR) has historically only been used with caution in the ...

Home February 04, 2021
Home
News | Heart Valve Technology

January 20, 2021 — The U.S. Centers for Medicare and Medicaid Services (CMS) revised its National Coverage Determination ...

Home January 20, 2021
Home
News | Heart Valve Technology

December 14, 2020 - Foldax Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an ...

Home December 14, 2020
Home
Feature | Heart Valve Technology

November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, more ...

Home November 17, 2020
Home
Feature | Heart Valve Technology | Dave Fornell, Editor

November 17, 2020 — Boston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge ...

Home November 17, 2020
Home
Videos | Heart Valve Technology

David Cohen, M.D., presents late-breaking data from the STS/ACC Transcatheter Valve Registry (TVT) showing the impact of ...

Home October 19, 2020
Home
Subscribe Now